Get started
Author

Loïc Chartier

Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies
2016 · Michel Meignan, Anne Ségolène Cottereau, et al. · Journal of Clinical Oncology · 326
Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial
2018 · Anne-Ségolène Cottereau, Annibale Versari, et al. · Blood · 193
PDF
Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT†
2020 · A.-S. Cottereau, M. Meignan, et al. · Annals of Oncology · 189
PDF
High total metabolic tumor volume at baseline predicts survival independent of response to therapy
2020 · Laetitia Vercellino, Anne-Segolene Cottereau, et al. · Blood · 186
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
2020 · Steven Le Gouill, Hervé Ghesquières, et al. · Blood · 77
PDF
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study
2018 · Anne Ségolène Cottereau, Annibale Versari, et al. · Blood · 72
PDF
Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma
2016 · Anne-Ségolène Cottereau, Sebastien Hapdey, et al. · Journal of Nuclear Medicine · 64
PDF
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
2022 · Catherine Thieblemont, Loic Chartier, et al. · Blood Advances · 43
PDF
Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed/refractory large B-cell lymphoma receiving CAR T cells
2022 · Jean Galtier, Laetitia Vercellino, et al. · Haematologica · 41
PDF
New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT
2021 · Anne-Ségolène Cottereau, Michel Meignan, et al. · Cancers · 35
PDF
A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the “REal world dAta in LYmphoma and survival in adults” (REALYSA) cohort
2021 · Hervé Ghesquières, Cédric Rossi, et al. · BMC Public Health · 19
PDF
Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance
2024 · Camille Laurent, Preeti Trisal, et al. · Blood · 18
PDF
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group
2022 · Raphaelle Aubrais, Krimo Bouabdallah, et al. · Blood Advances · 18
PDF
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration
2024 · Fabian Frontzek, Loïc Renaud, et al. · Leukemia · 14
Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies
2016 · Anne Ségolène Cottereau, Annibale Versari, et al. · Blood · 13
Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis
2023 · Catherine Thieblemont, Bettina Altmann, et al. · Blood Advances · 12
PDF
Validation of POD24 As a Robust Early Clinical End Point of Poor Survival in Mantle Cell Lymphoma from 1280 Patients on Clinical Trials
2023 · Clementine Sarkozy, Loïc Chartier, et al. · Blood · 10
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
2025 · Clémentine Sarkozy, Loïc Chartier, et al. · Blood Cancer Journal · 9
PDF
Interim PET after 4 cycles predicts outcome in histomolecularly confirmed primary mediastinal B-cell lymphoma
2025 · Vincent Camus, Thierry Molina, et al. · Blood Advances · 6
Long‐term follow‐up confirms the favourable prognostic impact of high numbers of tumour infiltrating CD3 T‐cells in follicular lymphoma patients treated by rituximab‐maintenance regimen
2023 · Camille Laurent, Maria Flores, et al. · British Journal of Haematology · 5
PDF
Outcome and Treatment of Relapsing Early Pet Negative Patients Included in the Eortc/lysa/fil H10 Trial on Stages I/ii Hodgkin Lymphoma
2019 · A. Gac, L. Chartier, et al. · Hematological Oncology · 4
Synthetic control arm from mixed clinical trials and real-world data from the LYSA group for untreated diffuse large B-cell lymphoma patients aged over 80 years: a bona fide strategy for innovative clinical trials
2025 · Valentin Letailleur, Isabelle Chaillol, et al. · Blood Cancer Journal · 3
PDF
Case presentation and management of Lyme disease patients: a 9-year retrospective analysis in France
2024 · Emeline Perthame, Loïc Chartier, et al. · Frontiers in Medicine · 3
Combining PET/CT and Ctdna Assessments at 6 Months from Induction Treatment Better Predicts Outcome in Previously Untreated Patients with Follicular Lymphoma: A Relevance Ancillary Lysa Study
2023 · Alexis Claudel, Anne Ségolène Cottereau, et al. · Blood · 3
CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.
2021 · Catherine Thieblemont, Bettina Altmann, et al. · Journal of Clinical Oncology · 3
Works count: 88
Citation count: 1,401
H-index: 14
I10-index: 17
Year
Topic
Type